13,023 Shares in Organon & Co. (NYSE:OGN) Acquired by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. purchased a new position in shares of Organon & Co. (NYSE:OGN) during the fourth quarter, Holdings Channel reports. The firm purchased 13,023 shares of the company’s stock, valued at approximately $188,000.

A number of other large investors have also added to or reduced their stakes in the stock. KLCM Advisors Inc. grew its position in Organon & Co. by 60.4% during the fourth quarter. KLCM Advisors Inc. now owns 999,099 shares of the company’s stock worth $14,407,000 after buying an additional 376,055 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Organon & Co. by 17.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 56,130 shares of the company’s stock worth $809,000 after purchasing an additional 8,492 shares during the last quarter. Everence Capital Management Inc. bought a new stake in Organon & Co. during the fourth quarter worth $400,000. Lecap Asset Management Ltd. bought a new stake in Organon & Co. during the fourth quarter worth $300,000. Finally, Louisiana State Employees Retirement System bought a new stake in Organon & Co. during the fourth quarter worth $1,844,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Insider Activity

In other news, insider Kirke Weaver purchased 2,720 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the purchase, the insider now owns 15,181 shares of the company’s stock, valued at $278,723.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.17% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group upped their target price on Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 20th.

Organon & Co. Price Performance

NYSE OGN opened at $18.43 on Friday. The business has a fifty day moving average price of $18.14 and a two-hundred day moving average price of $15.69. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.79. The stock has a market capitalization of $4.71 billion, a PE ratio of 4.61, a PEG ratio of 0.89 and a beta of 0.83.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.55 billion. As a group, sell-side analysts expect that Organon & Co. will post 4.08 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.08%. The ex-dividend date was Friday, February 23rd. Organon & Co.’s payout ratio is 28.00%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.